Jinshazhou Hospital of Guangzhou University of Chinese Medicine
Jinshazhou Hospital of Guangzhou University of Chinese Medicine
China, Guangzhou
Zhang Yanjun
30 years of experience
Clinic is certified :
The cost for radiation therapy for a brain tumor in China typically ranges from $13,800 to $26,400. Final pricing depends on the selected technology, treatment complexity, and city, with major hubs including Beijing, Shanghai, and Guangzhou. Patients save around 43% compared to the United States, where the average cost is $35,000. Standard inclusions often cover treatment planning, simulation, and radiation sessions.
Bookimed Expert Insight: Choosing a tertiary Class-III hospital like Jinshazhou Hospital offers high-volume expertise. This facility serves over 680,000 patients annually and holds OECI accreditation. Specialist physicians like Dr. Zhang Yanjun bring 30 years of experience to neuro-oncology. Many top Chinese centers provide multidisciplinary support specifically for international patients. This integration often includes translation and visa assistance within the medical journey.
| China | Turkey | Austria | |
| Radiation therapy for Brain Tumor | from $13,800 | from $3,250 | from $25,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Radiation therapy for Brain Tumor upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Radiation therapy for Brain Tumor and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Radiation therapy for Brain Tumor journey.
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Week 1-4 Post-Operation
Week 5-8 Post-Operation
Please note each patient"s experience with radiation therapy for a brain tumor may vary significantly depending on individual circumstances.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
30 years specializing in tumor imaging and radiation therapy, with extensive expertise in CNS tumors. Zhang Yanjun leads brain tumor radiation therapy at Jinshazhou Hospital.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.